Lawsuit Notice: $EMBC Legal News: Embecta Insulin Pen Issues and 57% Stock Drop Trigger Securities Fraud Class Action

A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock.

Embecta is a medical device company that produces insulin pens for patients with diabetes.

According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that "prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio."

As alleged, in truth, Embecta faced significant competition and "overall market softness for insulin pens and pen needles."

On May 5, 2026, Embecta announced disappointing Q2 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer.

Embecta also reported an "overall market volume softness for insulin pens and pen needles in the retail channel," admitting that "we have now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that we reported."

As a result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per share.

This news caused the price of Embecta common stock to decline $5.35 per share, or 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026.

If you invested in Embecta, you may have legal options and are encouraged to submit your information to the firm.